Acute myeloid leukemia (AML) is a hematological malignancy characterized by cytogenetic
and genomic alterations. Up to now, combination chemotherapy remains the standard …

Despite FDA approval of nine new drugs for patients with acute myeloid leukemia (AML) in
the United States over the last 4 years, AML remains a major area of unmet medical need …

Clonal hematopoiesis (CH) arises when a substantial proportion of mature blood cells is
derived from a single hematopoietic stem cell lineage. Using whole-genome sequencing of …

Histone H2A lysine 119 (H2AK119Ub) is monoubiquitinated by Polycomb repressive
complex 1 and deubiquitinated by Polycomb repressive deubiquitinase complex (PR-DUB) …

Gene mutations independent of BCR:: ABL1 have been identified in newly diagnosed
patients with chronic myeloid leukemia (CML) in chronic phase, whereby mutations in …

Cell identity is tightly controlled by specific transcriptional programs which require post-
translational modifications of histones. These histone modifications allow the establishment …

Biological events that contribute to the pathogenesis of myelodysplastic
syndromes/neoplasms (MDS) are becoming increasingly characterized and are being …

Acute myeloid leukemia (AML) is a heterogeneous hematopoietic neoplasm which results in
clonal proliferation of abnormally differentiated hematopoietic cells. In this review …

Repression of gene expression by protein complexes of the Polycomb group is a
fundamental mechanism that governs embryonic development and cell-type specification …

Myeloid malignancies develop through the accumulation of genetic and epigenetic
alterations that dysregulate hematopoietic stem cell (HSC) self-renewal, stimulate HSC …